Na Qiang, Junjie Ao, Masato Nakamura, Tetsuhiro Chiba, Yuko Kusakabe, Tatsuya Kaneko, Akane Kurosugi, Tadayoshi Kogure, Yaojia Ma, Jiaqi Zhang, Keita Ogawa, Motoyasu Kan, Terunao Iwanaga, Takafumi Sakuma, Kengo Kanayama, Hiroaki Kanzaki, Ryuta Kojima, Ryo Nakagawa, Takayuki Kondo, Shingo Nakamoto, Ryosuke Muroyama, Jun Kato, Naoya Mimura, Anqi Ma, Jian Jin, Naoya Kato
Enhancer of zeste homolog 2 (EZH2), a core component of polycomb repressive component 2 is overexpressed in a variety of cancers and recognized as a therapeutic target molecule. However, EZH2 possesses immunomodulatory functions in the tumor microenvironment (TME). The impact of EZH2 on TME of hepatocellular carcinoma (HCC) using immunocompetent mouse model was evaluated in the present study. UNC1999, an EZH2 inhibitor, impaired growth of the murine HCC cells (H22 cells) and induced apoptosis in a dose-dependent manner...
March 29, 2023: International Immunopharmacology